Table 1.
Clinicopathologic characteristics of patients treated with anti-LAG-3 immunotherapy.
| Patient Characteristics | Responders (n = 37) |
Non-responders (n = 16) | Total (n = 53) |
P value |
|---|---|---|---|---|
| Age (median, years) | 62 | 67 | 63 | – |
| Sex, n (%) | ||||
| Male | 24 (65) | 11 (69) | 35 (66) | P > .99 |
| Female | 13 (35) | 5 (31) | 18 (34) | |
| Elevated LDH, n (%) | 8 (22) | 10 (63) | 18 (34) | *P = .0098 |
| BRAF V600 mutation, n (%) | 12 (33) | 6 (38) | 18 (34) | P = .76 |
| Treatment, n (%) | ||||
| Anti-PD-1 + Anti-LAG-3 | 28 (76) | 14 (88) | 42 (79) | P = .47 |
| Anti-PD-1 + Anti-CTLA-4 + Anti-LAG-3 | 9 (24) | 2 (13) | 11 (21) | |
| Prior BRAFi, n (%) | 1 (3) | 5 (31) | 6 (11) | *P = .0074 |
| Prior immunotherapy, n (%) | 3 (8) | 8 (50) | 11 (21) | *P = .0014 |
| M stage (AJCC 8th edition), n (%) | ||||
| M0 | 6 (17) | 1 (6) | 7 (13) | UND |
| M1a | 2 (6) | 0 (0) | 2 (4) | |
| M1b | 13 (36) | 2 (11) | 15 (28) | |
| M1c | 14 (39) | 14 (78) | 28 (52) | |
| M1d | 1 (3) | 1 (6) | 2 (4) | |
| Response1, n (%) | ||||
| CR | 6 (16) | 0 (0) | 6 (11) | UND |
| PR | 31 (84) | 0 (0) | 31 (58) | |
| SD | 0 (0) | 4 (25) | 4 (8) | |
| PD2 | 0 (0) | 12 (75) | 12 (23) |
Abbreviations: Anti-PD-1 – anti-programmed cell death-1; anti-LAG-3 – anti-lymphocyte activation gene-3; anti-CTLA-4 – anti-cytotoxic T-lymphocyte activation-4; LDH – lactate dehydrogenase; AJCC – American Joint Committee on Cancer; CR – complete response; PR – partial response; SD – stable disease; PD – progressive disease; % - percentage; UND – undetermined due to small numbers.
Fisher’s exact test P values are reported where appropriate. *P < .05.
1Patients were stratified into response groups based on RECIST 1.1 criteria. Patients with CR and PR were classified as responders, while patients with SD and PD were classified as non-responders.
2One patient with no imaging was categorized as having progressive disease based on their time to progression (<6 months) and cause of death (melanoma).